143 related articles for article (PubMed ID: 34856908)
1. The Prevalence and Associated Factors of Reduced Bone Mineral Density (BMD) Among Men with Suppressed Viral Load Taking Antiretroviral Therapy.
Ozcan SN; Sevgi DY; Oncul A; Gunduz A; Pehlivan O; Terlemez R; Kuran B; Dokmetas I
Curr HIV Res; 2022; 20(1):74-81. PubMed ID: 34856908
[TBL] [Abstract][Full Text] [Related]
2. Bone mineral density changes among people living with HIV who have started with TDF-containing regimen: A five-year prospective study.
Han WM; Wattanachanya L; Apornpong T; Jantrapakde J; Avihingsanon A; Kerr SJ; Teeratakulpisarn N; Jadwattanakul T; Chaiwatanarat T; Buranasupkajorn P; Ramautarsing R; Phanuphak N; Sunthornyothin S; Ruxrungtham K; Phanuphak P;
PLoS One; 2020; 15(3):e0230368. PubMed ID: 32210458
[TBL] [Abstract][Full Text] [Related]
3. Association between Nonalcoholic Fatty Liver Disease and Bone Mineral Density in HIV-Infected Patients Receiving Long-term TDF-Based Antiretroviral Therapy.
Xu Z; He P; Xian J; Lu W; Shu J; Luo W; Gan C; Ke R; Xia J; Han Z; Huang M
Curr HIV Res; 2021; 19(1):40-46. PubMed ID: 32940183
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV.
Hoy JF; Richardson R; Ebeling PR; Rojas J; Pocock N; Kerr SJ; Martinez E; Carr A;
AIDS; 2018 Sep; 32(14):1967-1975. PubMed ID: 29927785
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and Risk Factors of Low Bone Mineral Density in HIV/AIDS Patients: A Chinese Cross-Sectional Study.
Meng W; Chen M; Song Y; Zhang H; Xie R; Zhang F
J Acquir Immune Defic Syndr; 2022 Jul; 90(3):360-368. PubMed ID: 35315797
[TBL] [Abstract][Full Text] [Related]
6. Reduced bone mineral density among HIV-infected, virologically controlled young men: prevalence and associated factors.
Shaiykova A; Pasquet A; Goujard C; Lion G; Durand E; Bayan T; Lachâtre M; Choisy P; Ajana F; Bourdic K; Viget N; Riff B; Quertainmont Y; Cortet B; Boufassa F; Chéret A
AIDS; 2018 Nov; 32(18):2689-2696. PubMed ID: 30234605
[TBL] [Abstract][Full Text] [Related]
7. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.
McComsey GA; Kitch D; Daar ES; Tierney C; Jahed NC; Tebas P; Myers L; Melbourne K; Ha B; Sax PE
J Infect Dis; 2011 Jun; 203(12):1791-801. PubMed ID: 21606537
[TBL] [Abstract][Full Text] [Related]
8. Effects of renal tubular dysfunction on bone in tenofovir-exposed HIV-positive patients.
Hamzah L; Samarawickrama A; Campbell L; Pope M; Burling K; Fisher M; Gilleece Y; Walker-Bone K; Post FA
AIDS; 2015 Sep; 29(14):1785-1792. PubMed ID: 26372384
[TBL] [Abstract][Full Text] [Related]
9. Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV.
Klassen KM; Kimlin MG; Fairley CK; Emery S; Anderson PH; Ebeling PR;
Osteoporos Int; 2016 May; 27(5):1737-45. PubMed ID: 26659069
[TBL] [Abstract][Full Text] [Related]
10. Bone Metabolism in Men who Live with HIV Aged 50 years and Over: Impact of Infection Duration.
Caglar B; Durcan E; Karaali R; Balkan II; Kaya SY; Yavuzer H; Konukoglu D; Aygun G; Saltoglu N; Bulut IN; Sonmezoglu K; Kadioglu P; Mete B; Tabak OF
Curr HIV Res; 2024; 22(1):65-71. PubMed ID: 38279729
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal change in bone mineral density among Chinese individuals with HIV after initiation of antiretroviral therapy.
Guo F; Song X; Li Y; Guan W; Pan W; Yu W; Li T; Hsieh E
Osteoporos Int; 2021 Feb; 32(2):321-332. PubMed ID: 32803316
[TBL] [Abstract][Full Text] [Related]
12. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors.
Goh SSL; Lai PSM; Tan ATB; Ponnampalavanar S
Osteoporos Int; 2018 Mar; 29(3):595-613. PubMed ID: 29159533
[TBL] [Abstract][Full Text] [Related]
13. Effect of HIV infection on growth and bone density in peripubertal children in the era of antiretroviral therapy: a cross-sectional study in Zimbabwe.
Rukuni R; Rehman AM; Mukwasi-Kahari C; Madanhire T; Kowo-Nyakoko F; McHugh G; Filteau S; Chipanga J; Simms V; Mujuru H; Ward KA; Ferrand RA; Gregson CL
Lancet Child Adolesc Health; 2021 Aug; 5(8):569-581. PubMed ID: 34139202
[TBL] [Abstract][Full Text] [Related]
14. The renal-bone axis in older people living with HIV on stable antiretroviral therapy: A sub-analysis of the GS-US-104-0423 study.
Alvarez E; Campbell L; Tinago W; Garcia-Leon A; Walsh I; Brady JJ; Burling K; Noe S; Neuville MF; Jouret F; Jamshidian F; Graham H; Rhee M; Mallon PW; Post FA
Antivir Ther; 2022 Aug; 27(4):13596535221094898. PubMed ID: 36000318
[TBL] [Abstract][Full Text] [Related]
15. High Prevalence of Low Bone Mineral Density and Substantial Bone Loss over 4 Years Among HIV-Infected Persons in the Era of Modern Antiretroviral Therapy.
Escota GV; Mondy K; Bush T; Conley L; Brooks JT; Önen N; Patel P; Kojic EM; Henry K; Hammer J; Wood KC; Lichtenstein KA; Overton ET
AIDS Res Hum Retroviruses; 2016 Jan; 32(1):59-67. PubMed ID: 26366785
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and risk factors for osteopenia/osteoporosis in an HIV-infected male population.
Tomazic J; Ul K; Volcansek G; Gorensek S; Pfeifer M; Karner P; Prezelj J; Vidmar G; Vidmar L
Wien Klin Wochenschr; 2007; 119(21-22):639-46. PubMed ID: 18043884
[TBL] [Abstract][Full Text] [Related]
17. Effect of Antiretroviral Therapy on Bone and Renal Health in Young Adults Infected With HIV in Early Life.
Unsal AB; Mattingly AS; Jones SE; Purdy JB; Reynolds JC; Kopp JB; Hazra R; Hadigan CM
J Clin Endocrinol Metab; 2017 Aug; 102(8):2896-2904. PubMed ID: 28531309
[TBL] [Abstract][Full Text] [Related]
18. Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy.
Kalayjian RC; Albert JM; Cremers S; Gupta SK; McComsey GA; Klingman KL; Fichtenbaum CJ; Brown TT; Taiwo BO;
AIDS; 2018 Nov; 32(17):2517-2524. PubMed ID: 30134291
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of and risk factors for low bone mineral density in Spanish treated HIV-infected patients.
Cervero M; Torres R; Agud JL; Alcázar V; Jusdado JJ; García-Lacalle C; Moreno S
PLoS One; 2018; 13(4):e0196201. PubMed ID: 29709013
[TBL] [Abstract][Full Text] [Related]
20. Frailty in HIV infected people: a new risk factor for bone mineral density loss.
Bregigeon S; Galinier A; Zaegel-Faucher O; Cano CE; Obry V; Laroche H; Trijau S; Saout A; Poizot-Martin I
AIDS; 2017 Jul; 31(11):1573-1577. PubMed ID: 28426535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
